<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    ESSA Pharma Inc.

    ESSA Pharma Inc.

    With a focus on the development of small molecule drugs for the treatment of cance...

    With a focus on the development of small molecu...

    Filing Type:    PU
    Orchard Therapeutics plc

    Orchard Therapeutics plc

    Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...

    Orchard Therapeutics is a fully integrated comm...

    Filing Type:    PU
    KemPharm, Inc.

    KemPharm, Inc.

    KemPharmÂŽ is a clinical-stage specialty pharmaceutical company engaged in the dis...

    KemPharmÂŽ is a clinical-stage specialty pharma...

    Filing Type:    PU
    Bioanalytical Systems, Inc.

    Bioanalytical Systems, Inc.

    BASi provides drug discovery and development services and analytical instruments t...

    BASi provides drug discovery and development se...

    Filing Type:    PU
    Organovo Holdings, Inc.

    Organovo Holdings, Inc.

    Organovo is a biotech platform company that has developed a leadership position wi...

    Organovo is a biotech platform company that has...

    Filing Type:    PU
    Vermillion, Inc.

    Vermillion, Inc.

    We are dedicated to the discovery, development, and commercialization of novel hig...

    We are dedicated to the discovery, development,...

    Filing Type:    PU
    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...

    Harpoon Therapeutics is a clinical-stage immuno...

    Filing Type:    PU
    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics, Inc.

    Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...

    Atara Biotherapeutics is a leading off-the-shel...

    Filing Type:    PU
    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...

    Trillium Therapeutics Inc. is a clinical stage ...

    Filing Type:    PU
    Incyte Corporation

    Incyte Corporation

    Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...

    Incyte Corporation is a Wilmington, Delaware-ba...

    Filing Type:    PU
    Fate Therapeutics, Inc.

    Fate Therapeutics, Inc.

    We are a biopharmaceutical company dedicated to the development of programmed cell...

    We are a biopharmaceutical company dedicated to...

    Filing Type:    PU
    Blueprint Medicines Corporation

    Blueprint Medicines Corporation

    Blueprint Medicines is a precision therapy company striving to improve human healt...

    Blueprint Medicines is a precision therapy comp...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.